A new vaccine against advanced cutaneous melanoma will be available to UK patients through an NHS program

<p>The UK's National Health Service is launching an innovative vaccine, iSCICIB1+, for patients with advanced cutaneous melanoma to improve the immune system's response to immunotherapy treatments. The program, part of the Cancer Vaccine Launch Pad, will enable rapid access to clinical trials, targeting 10,000 patients by 2030. The first patients are expected to start treatment next month, and the initiative highlights the potential of vaccines to transform cancer care and save lives. Melanoma is the fifth most common cancer in the UK and early monitoring is essential for effective treatment.